Find Pretomanid manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Pa-824, 187235-37-6, Pa 824, Pa824, (s)-2-nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine, (s)-pa 824
Molecular Formula
C14H12F3N3O5
Molecular Weight
359.26  g/mol
InChI Key
ZLHZLMOSPGACSZ-NSHDSACASA-N
FDA UNII
2XOI31YC4N

Pretomanid
Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens. Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB. It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. Unlike other therapeutic regimens for the treatment of resistant TB, which may take 18 months or longer and may not be effective, the pretomanid-containing regimen allows for a more efficacious and shorter duration of treatment with fewer drugs.
1 2D Structure

Pretomanid

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
2.1.2 InChI
InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
2.1.3 InChI Key
ZLHZLMOSPGACSZ-NSHDSACASA-N
2.1.4 Canonical SMILES
C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
2.1.5 Isomeric SMILES
C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
2XOI31YC4N
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5h-imidazo(2,1-b)(1,3)oxazine

2. Pa 824

3. Pa-824

4. Pa824 Cpd

2.3.2 Depositor-Supplied Synonyms

1. Pa-824

2. 187235-37-6

3. Pa 824

4. Pa824

5. (s)-2-nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine

6. (s)-pa 824

7. 2xoi31yc4n

8. Chembl227875

9. Mmv688755

10. (6s)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine

11. (6s)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine

12. (6s)-2-nitro-6-{[4-(trifluoromethoxy)phenyl]methoxy}-5h,6h,7h-imidazo[2,1-b][1,3]oxazine

13. Pretomanid [usan:inn]

14. Unii-2xoi31yc4n

15. Pretomanid (tn)

16. Pa-824(pretomanid)

17. Pretomanid [mi]

18. Pretomanid [inn]

19. Pretomanid (usan/inn)

20. Pretomanid [usan]

21. Pretomanid [who-dd]

22. Mls006011141

23. Schembl2983011

24. Dtxsid8041163

25. Pretomanid [orange Book]

26. Gtpl11172

27. Ex-a1749

28. Zinc3821675

29. Bdbm50363237

30. Cs1245

31. Mfcd06809939

32. S1162

33. Akos024464713

34. Ccg-268145

35. Db05154

36. Ds-7321

37. 2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5h-imidazo(2,1-b)(1,3)oxazine

38. Ncgc00346682-01

39. Ncgc00346682-02

40. Ac-25501

41. Hy-10844

42. Smr004702918

43. P2718

44. Sw220281-1

45. D10722

46. A855886

47. Sr-05000022748

48. Q7118312

49. Sr-05000022748-1

50. (3s)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2h-3,4-dihydroimidazo(2,1-b)oxazine

51. (s)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5h-imidazo(2,1-b)(1,3)oxazine

52. {4-[((3s)-6-nitro(2h,3h,4h-imidazolo[2,1-b]1,3-oxazaperhydroin-3-yloxy))methyl]phenoxy}trifluoromethane

53. 5h-imidazo(2,1-b)(1,3)oxazine, 6,7-dihydro-2-nitro-6-((4-(trifluoromethoxy)phenyl)methoxy)-, (6s)-

54. Pretomanid;(6s)-6,7-dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5h-imidazo[2,1-b][1,3]oxazine

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 359.26 g/mol
Molecular Formula C14H12F3N3O5
XLogP32.8
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count9
Rotatable Bond Count4
Exact Mass359.07290498 g/mol
Monoisotopic Mass359.07290498 g/mol
Topological Polar Surface Area91.3 Ų
Heavy Atom Count25
Formal Charge0
Complexity468
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Pretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrug-resistant (MDR), extensively drug-resistant (XDR), and treatment-intolerant forms of pulmonary tuberculosis (TB). It is important to note that the following conditions are not approved indications for pretomanid therapy, according to the FDA: Drug-sensitive (DS) tuberculosis, latent tuberculosis caused by M.tuberculosis, extra-pulmonary tuberculosis caused by M.tuberculosis, and multidrug-resistant TB that is not treatment-intolerant or nonresponsive to conventional TB therapy.


Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.


Treatment of multi-drug-resistant tuberculosis


5 Pharmacology and Biochemistry
5.1 Pharmacology

Pretomanid kills the actively replicating bacteria causing tuberculosis, known as Mycobacterium tuberculosis, and shortens the duration of treatment in patients who suffer from resistant forms of pulmonary TB by killing dormant bacteria. In rodent models of tuberculosis infection, pretomanid administered in a regimen with bedaquiline and linezolid caused a significant reduction in pulmonary bacterial cell counts. A decrease in the frequency of TB relapses at 2 and 3 months after treatment was observed after the administration of this regimen, when compared to the administration of a 2-drug regimen. Successful outcomes have been recorded for patients with XDR and MDR following a clinical trial of the pretomanid regimen, demonstrating a 90% cure rate after 6 months. **A note on cardiac QT prolongation, hepatotoxicity, and myelosuppression** This drug has the propensity to caused cardiac QT interval prolongation and significant hepatotoxicity, as well as myelosuppression. Caution must be observed during the administration of this drug.


5.2 ATC Code

J04


J - Antiinfectives for systemic use

J04 - Antimycobacterials

J04A - Drugs for treatment of tuberculosis

J04AK - Other drugs for treatment of tuberculosis

J04AK08 - Pretomanid


5.3 Absorption, Distribution and Excretion

Absorption

This drug is absorbed in the gastrointestinal tract. The steady-state Cmax of pretomanid was estimated to be 1.7 g/mL after a single 200mg oral dose. In a separate pharmacokinetic modeling study, the Cmax of a 200mg dose was 1.1 g/ml. Tmax in a study of healthy subjects in the fed or unfed state was achieved within 4 to 5 hours. The AUC in the same study was found to be about 28.1 ghr/mL in the fasted state and about 51.6 ghr/mL in the fed state, showing higher absorption when taken with high-calorie and high-fat food.


Route of Elimination

Healthy adult male volunteers were administered a 1,100 mg oral dose of radiolabeled pretomanid in one pharmacokinetic study. An average of about 53% of the radioactive dose was found to be excreted in the urine. Approximately 38% was measured mainly as metabolites in the feces. A estimated 1% of the radiolabeled dose was measured as unchanged drug in the urine.


Volume of Distribution

A pharmacokinetic modeling study estimated the volume of distribution at 130 5L. A pharmacokinetic study in healthy volunteers determined a volume of distribution of about 180 51.3L in fasted state and 97.0 17.2L in the fed state.


Clearance

The clearance of pretomanid in a pharmacokinetic simulation study has been estimated at 4.8 0.2 liters/h. According to the FDA label, the clearance of a single 200 mg oral dose of pretomanid is estimated to be 7.6 liters/h in the fasted state, and 3.9 liters/h in the fed state.


5.4 Metabolism/Metabolites

Various reductive and oxidative pathways are responsible for pretomanid metabolism, with no single major metabolic pathway identified. According to in vitro studies, CYP3A4 is responsible for a 20% contribution to the metabolism of pretomanid.


5.5 Biological Half-Life

The elimination half-life was determined to be 16.9-17.4 hours in a pharmacokinetic study of healthy subjects. An FDA briefing document reports a half-life of 18 hours.


5.6 Mechanism of Action

Pretomanid is a prodrug which is metabolically activated by a nitroreductase enzyme, known as Ddn, producing various active metabolites that are responsible for its other therapeutic actions, particularly the induction of nitric oxide. The nitroreductase enzyme which activates pretomanid is deazaflavin dependent and relies on reduced cofactor F420. Reduction of F420 occurs via the enzyme glucose-6-phosphate dehydrogenase. Reduction of pretomanid's imidazole ring at the C-3 position causes the formation of the metabolites, which include a des-nitro derivative. The formation of this derivative leads to increased levels of nitric oxide, leading to bactericidal activities under anaerobic conditions via its action as a bacterial respiratory poison. Bactericidal activity against anaerobes is reported to be associated with a shortened duration of antibiotic treatment. Pretomanid exerts aerobic bactericidal effects through its inhibitory actions on bacterial cell wall mycolic acid biosynthesis. This allows for the killing of actively replicating Mycobacterium tuberculosis bacteria, resulting in the treatment of active tuberculosis infection. The molecular mechanism of the above bactericidal effects is poorly understood at this time, but may involve effects exerted on various genes that affect the cell wall, including the fasI and fasII as well as the efpA and iniBAC operons. Other possible targets include the genes of the cyd operon. The clinical effects of the above target relations are unknown at this time.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Pretomanid Manufacturers

A Pretomanid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pretomanid, including repackagers and relabelers. The FDA regulates Pretomanid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pretomanid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Pretomanid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Pretomanid Suppliers

A Pretomanid supplier is an individual or a company that provides Pretomanid active pharmaceutical ingredient (API) or Pretomanid finished formulations upon request. The Pretomanid suppliers may include Pretomanid API manufacturers, exporters, distributors and traders.

click here to find a list of Pretomanid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Pretomanid USDMF

A Pretomanid DMF (Drug Master File) is a document detailing the whole manufacturing process of Pretomanid active pharmaceutical ingredient (API) in detail. Different forms of Pretomanid DMFs exist exist since differing nations have different regulations, such as Pretomanid USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Pretomanid DMF submitted to regulatory agencies in the US is known as a USDMF. Pretomanid USDMF includes data on Pretomanid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pretomanid USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Pretomanid suppliers with USDMF on PharmaCompass.

Pretomanid WC

A Pretomanid written confirmation (Pretomanid WC) is an official document issued by a regulatory agency to a Pretomanid manufacturer, verifying that the manufacturing facility of a Pretomanid active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pretomanid APIs or Pretomanid finished pharmaceutical products to another nation, regulatory agencies frequently require a Pretomanid WC (written confirmation) as part of the regulatory process.

click here to find a list of Pretomanid suppliers with Written Confirmation (WC) on PharmaCompass.

Pretomanid GMP

Pretomanid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Pretomanid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pretomanid GMP manufacturer or Pretomanid GMP API supplier for your needs.

Pretomanid CoA

A Pretomanid CoA (Certificate of Analysis) is a formal document that attests to Pretomanid's compliance with Pretomanid specifications and serves as a tool for batch-level quality control.

Pretomanid CoA mostly includes findings from lab analyses of a specific batch. For each Pretomanid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Pretomanid may be tested according to a variety of international standards, such as European Pharmacopoeia (Pretomanid EP), Pretomanid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pretomanid USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty